U.S. Hydronephrosis Market Size, Share & Forecast 2026–2032

ID: MR-11275 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Hydronephrosis Market
  • ✓Market Size 2024: USD 1.82 billion
  • ✓Market Size 2032: USD 2.61 billion
  • ✓CAGR: 4.6%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Ambulatory Shift Reshaping Stent Demand: Ureteral stent placements are migrating from inpatient wards to ambulatory urology suites. Boston Scientific and Cook Medical hold most of that volume, and Medicare's expanded ASC covered procedure list accelerates the move. Suppliers without outpatient-sized packaging will lose share.
FINDING 02
Imaging Outpaces Surgical Growth: Consensus treats robotic pyeloplasty as the growth engine, but diagnostic ultrasound drives the larger dollar expansion. Point-of-care ultrasound adoption across emergency departments, supplied by GE HealthCare and Philips, pulls detection earlier in prenatal and pediatric pathways.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Ambulatory Distribution Now: Medical device suppliers should secure ambulatory surgical center contracts and GPO listings with Vizient and Premier before the first quarter of 2026. Outpatient urology volume is consolidating under group purchasing agreements, and late entrants will face closed formularies through 2032.

U.S. Hydronephrosis: Market Overview

The U.S. hydronephrosis market is distinct because it is not a standalone product category but a clinical outcome addressed through diagnostic imaging, urological devices, and reconstructive surgery. Domestic spending reached USD 1.82 billion in 2024, representing roughly 38% of global spending on obstruction-related urology care. Unlike global demand, which is driven by infection and stone management in low-income settings, U.S. demand reflects prenatal screening pathways, high pediatric detection rates, and a growing elderly population with benign prostatic hyperplasia.

Structurally, the market is split between capital-intensive imaging and disposable urological consumables. Ultrasound and CT urography generate the largest revenue pool, while ureteral stents, nephrostomy tubes, and ureteroscopy sheaths from Boston Scientific, Cook Medical, and Teleflex account for recurring supply revenue. The market is more concentrated in hospital purchasing than most global markets, because Medicare reimbursement under the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center payment rules sets pricing for nearly every procedure.

Growth Drivers in U.S. Hydronephrosis Care

Prenatal detection is the first driver. The American Academy of Pediatrics follows antenatal hydronephrosis grading guidance, and roughly 3.6 million U.S. live births each year feed postnatal urological follow-up. Medicaid expansion in 40 states has widened access to these pathways, and pediatric referrals for moderate to severe cases drive repeat ultrasound and voiding cystourethrography volumes across children's hospitals. Renal ultrasound codes CPT 76770 and 76775 remain reimbursed at stable rates, supporting high utilization.

An aging population adds a second driver. Benign prostatic hyperplasia affects most men over 60, and bladder outlet obstruction frequently produces secondary hydronephrosis that requires stenting or nephrostomy. The Census Bureau projects 73 million Americans aged 65 and older by 2030, expanding the pool for these interventions. The third driver is robotic reconstruction, as Intuitive Surgical's da Vinci systems, installed across thousands of U.S. hospitals, increasingly support pyeloplasty for ureteropelvic junction obstruction in adults and children.

Market Restraints and Entry Barriers

Entry is constrained first by FDA premarket requirements. Ureteral stents, nephrostomy catheters, and ureteroscopes are generally Class II devices under 21 CFR Part 876, cleared through 510(k) notifications against an existing predicate. The Quality Management System Regulation, which incorporates ISO 13485 from February 2, 2026, adds audit burden for suppliers without established U.S. manufacturing controls. Imaging software that grades hydronephrosis severity without a predicate follows the longer De Novo route, adding months to launch timelines.

Pricing and incumbency present the second barrier. Medicare's Ambulatory Surgical Center payment system and group purchasing organizations such as Vizient and Premier lock multi-year contracts, leaving new entrants competing against Cook Medical and Boston Scientific on established formularies. Distribution complexity adds cost, because stents require sterile packaging, hospital value analysis committee approval, and rapid reorder support across roughly 6,000 acute-care hospitals.

Market Opportunities in the United States

Ambulatory urology is the nearest opportunity. Medicare has progressively expanded the ASC covered procedures list to include urological endoscopy, and an estimated USD 410 million of ureteral stent and ureteroscopy consumable spend still sits in hospital outpatient departments. That volume is positioned to migrate to ASCs by 2030, giving suppliers with outpatient-sized packaging and bundled pricing a window before contracts consolidate. Urology ASCs in Texas, Florida, and Georgia show the fastest case growth, making regional distribution agreements the first priority.

Point-of-care ultrasound in urgent care and primary care is the second opportunity. Handheld ultrasound units priced below USD 10,000 are entering urgent care chains, and an estimated USD 260 million of renal screening demand in these settings remains underserved by specialist imaging. Urgent care chains operating over 1,000 U.S. clinics provide the distribution backbone. AI-assisted grading software cleared through the FDA De Novo pathway can capture this segment before 2028, because few competitors have completed clearance.

Market at a Glance

MetricValue
Market Size 2024USD 1.82 billion
Market Size 2032USD 2.61 billion
Growth Rate (CAGR)4.6%
Most Critical Decision FactorAlignment with ASC and outpatient payment rules
Largest RegionSouth Region
Competitive StructureModerately consolidated, with the top five suppliers holding majority share

Leading Market Participants

  • Boston Scientific
  • Cook Medical
  • Teleflex
  • Coloplast
  • Becton Dickinson
  • Olympus Corporation
  • Karl Storz
  • Intuitive Surgical
  • GE HealthCare
  • Philips

Regulatory and Policy Environment

Device commercialization is governed by the Federal Food, Drug, and Cosmetic Act, with ureteral stents and nephrostomy catheters cleared by the FDA's Center for Devices and Radiological Health through 510(k) notifications, targeting a 90 FDA-day review goal under the Medical Device User Fee Amendments. The Quality Management System Regulation takes full effect on February 2, 2026, requiring manufacturers to align quality systems with ISO 13485:2016. Hydronephrosis grading software without a predicate device requires De Novo classification, a process that typically extends launch timelines by several months.

Reimbursement rules are set by the Centers for Medicare and Medicaid Services. The CY2025 Medicare Physician Fee Schedule and Outpatient Prospective Payment System final rules determine procedure payment, while the Ambulatory Surgical Center covered procedures list governs site-of-service decisions for urological surgery. Medicaid expansion, backed by a 90% federal match under the Affordable Care Act, supports pediatric access. Manufacturers must comply with the Anti-Kickback Statute and Open Payments reporting under the Sunshine Act, with annual disclosure filed each spring.

Long-Term Outlook for Hydronephrosis in the U.S.

By 2032, the U.S. hydronephrosis market is projected to reach USD 2.61 billion, with outpatient settings capturing a rising share of stent, nephrostomy, and ureteroscopy procedures. Ultrasound will remain the primary diagnostic entry point for suspected obstruction, while CT urography retains share in adult trauma and oncologic staging. Robotic reconstruction will grow steadily rather than rapidly, because pediatric and adult pyeloplasty volumes remain constrained by surgeon training capacity and case scheduling at academic centers.

Competitive dynamics will hinge on outpatient-ready packaging, AI-assisted severity grading, and value-based contracts with integrated delivery networks. Boston Scientific and Cook Medical will defend stent share through formulary breadth, while point-of-care ultrasound suppliers gain ground in primary care and urgent care. Prenatal screening guidance and Medicaid coverage will provide the clearest demand floor through 2032, regardless of cyclical hospital capital budgets.

Frequently Asked Questions

Most stents, catheters, and ureteroscopes qualify as Class II devices cleared through 510(k) notification against an existing predicate. Software that grades hydronephrosis without a predicate requires the longer De Novo pathway.
Payment and site-of-service changes take effect through the annual CY Physician Fee Schedule and OPPS final rules, typically published in November for January 1 implementation. Suppliers should align product packaging and pricing with these cycles.
Vizient and Premier account for the majority of hospital contracts for urological consumables in the U.S. Listing on their agreements is a prerequisite for most hospital value analysis committee approvals.
Medicaid expansion in 40 states has widened coverage for prenatal and pediatric follow-up imaging and procedures. State-level formularies and prior authorization rules still vary, so market access requires state-by-state reimbursement planning.
Incumbent suppliers hold multi-year contracts with integrated delivery networks, limiting open hospital access. Late entrants that miss the 2026 to 2027 ambulatory contracting cycle face closed formularies through 2032.

Market Segmentation

By Care Setting
  • Hospitals
  • Ambulatory Surgical Centers
  • Urology Clinics
  • Ambulatory Imaging Centers
  • Children's Hospitals
By Patient Age Group
  • Prenatal and Neonatal
  • Pediatric
  • Adult
  • Geriatric
By Diagnostic Method
  • Ultrasonography
  • CT Urography
  • MR Urography
  • Nuclear Renography
  • Voiding Cystourethrography

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Hydronephrosis - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Care Setting Insights
4.1 Hospitals
4.2 Ambulatory Surgical Centers
4.3 Urology Clinics
4.4 Ambulatory Imaging Centers
4.5 Others
Chapter 05 Patient Age Group Insights
5.1 Prenatal and Neonatal
5.2 Pediatric
5.3 Adult
5.4 Geriatric
5.5 Others
Chapter 06 Diagnostic Method Insights
6.1 Ultrasonography
6.2 CT Urography
6.3 MR Urography
6.4 Nuclear Renography
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Boston Scientific
7.2.2 Cook Medical
7.2.3 Teleflex
7.2.4 Coloplast
7.2.5 Becton Dickinson
7.2.6 Olympus Corporation
7.2.7 Karl Storz
7.2.8 Intuitive Surgical
7.2.9 GE HealthCare
7.2.10 Philips
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.